Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada - Full Text View

Sponsored by:	Pfizer
Information provided by:	Pfizer
ClinicalTrials.gov Identifier:	NCT00334750

Purpose

This descriptive, non-interventional study will collect information on the presence of risk factors in newly diagnosed OH and OAG patients in Canada.

Condition	Intervention
Glaucoma, Open-Angle Ocular Hypertension	Other: There is no intervention in this study.

Genetics Home Reference related topics: early-onset glaucoma

MedlinePlus related topics: Glaucoma High Blood Pressure

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Prospective
Official Title:	Distribution of Risk Factors Amongst Ocular Hypertension and Open-Angle Glaucoma Patients in Canada

Further study details as provided by Pfizer:

Primary Outcome Measures:

To describe the presence and distribution of risk factors in subjects diagnosed with OH or OAG stratified according to geographic distribution in a Canadian population in the ophthalmologist practice. [ Time Frame: duration of study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

To describe the severity of disease at the time of diagnosis and to determine if there is a correlation between risk factors, or number of risk factors, and the severity of disease at presentation. [ Time Frame: duration of study ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	400
Study Start Date:	November 2007
Estimated Study Completion Date:	December 2008
Estimated Primary Completion Date:	December 2008 (Final data collection date for primary outcome measure)

Groups/Cohorts	Assigned Interventions
There is no intervention in this study This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.	Other: There is no intervention in this study. This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Canadian population

Criteria

Inclusion Criteria:

Subjects diagnosed at study visit or within 3 months of visit with OH
OAG (to include POAG, NTG, pigmentary and pseudoexfoliation glaucoma)

Exclusion Criteria:

No prior treatment for OH or OAG
No prior ocular surgery or history of ocular trauma

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00334750

Contacts

Contact: Pfizer CT.gov Call Center

1-800-718-1021

Locations

Canada, Alberta
Pfizer Investigational Site	Recruiting
Calgary, Alberta, Canada, T3E 7M8
Pfizer Investigational Site	Recruiting
Edmonton, Alberta, Canada, T5H 0X5
Pfizer Investigational Site	Recruiting
Edmonton, Alberta, Canada, T5H 3V9
Canada, British Columbia
Pfizer Investigational Site	Recruiting
Nanaimo, British Columbia, Canada, V9R 5B6
Pfizer Investigational Site	Recruiting
Vancouver, British Columbia, Canada, V6K 1V7
Pfizer Investigational Site	Recruiting
Williams Lake, British Columbia, Canada, V2G 1H1
Canada, Manitoba
Pfizer Investigational Site	Recruiting
Winnipeg, Manitoba, Canada, R3C 0N2
Canada, Ontario
Pfizer Investigational Site	Recruiting
Brampton, Ontario, Canada, L6V 1B4
Pfizer Investigational Site	Recruiting
Mississauga, Ontario, Canada, L5L 1W8
Pfizer Investigational Site	Recruiting
Oakville, Ontario, Canada, L6H 3P1
Pfizer Investigational Site	Recruiting
Toronto, Ontario, Canada, M4N 3M5
Pfizer Investigational Site	Recruiting
Toronto, Ontario, Canada, M5T 2S8
Pfizer Investigational Site	Recruiting
London, Ontario, Canada, N6A 4V2
Pfizer Investigational Site	Recruiting
Toronto, Ontario, Canada, M5M 1B2
Pfizer Investigational Site	Recruiting
Hamilton, Ontario, Canada, L8M 1L6
Pfizer Investigational Site	Recruiting
Oakville, Ontario, Canada, L6L 5G8
Pfizer Investigational Site	Recruiting
Alliston, Ontario, Canada, L9R 1W7
Pfizer Investigational Site	Recruiting
Downsview, Ontario, Canada, M3N 2V6
Canada, Quebec
Pfizer Investigational Site	Recruiting
Sherbrooke, Quebec, Canada, J1K 1EB
Pfizer Investigational Site	Recruiting
Montreal, Quebec, Canada, H1V 1G5
Pfizer Investigational Site	Recruiting
Montreal, Quebec, Canada, H1T 2M4
Canada, Saskatchewan
Pfizer Investigational Site	Recruiting
Saskatoon, Saskatchewan, Canada, S7K 3H3

Sponsors and Collaborators

Pfizer

Investigators

Study Director:

Pfizer CT.gov Call Center

Pfizer

More Information

To obtain contact information for a study center near you, click here. This link exits the ClinicalTrials.gov site

Responsible Party:	Pfizer Inc ( Director, Clinical Trial Disclosure Group )
Study ID Numbers:	A6111125
Study First Received:	June 5, 2006
Last Updated:	January 5, 2009
ClinicalTrials.gov Identifier:	NCT00334750
Health Authority:	Canada: Ethics Review Committee

Keywords provided by Pfizer:

Glaucoma, Open-Angle Ocular Hypertension Risk factors Canadian

Study placed in the following topic categories:

Glaucoma
Eye Diseases
Glaucoma, Open-Angle

Vascular Diseases
Hypertension
Ocular Hypertension

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 16, 2009